EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer

Li, Kun; Tan, Guangqing; Zhang, Xin; Lu, Wei-Yu; Ren, Jingyi; Si, Yuewen; Adu‐Gyamfi, Enoch Appiah; Li, Fangfang; Wang, Yingxiong; Xie, Biao; Wang, Meijiao

doi:10.3390/biom12121756

Cited by 6 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To predict potentially more appropriate treatment for LUAD patients, we evaluated IPS scores, TIDE scores, and sensitivity to common chemotherapy drugs in two groups. Multiple reports suggested that high IPS scores and low TIDE scores may be related to better immunotherapy responses. , Cisplatin, oxaliplatin, and nilotinib are common chemotherapy drugs used to treat cancer. In the present study, it was discovered that individuals exhibiting a favorable prognosis within the LR group exhibited elevated IPS scores and decreased TIDE scores, which was opposed to that of the HR group.…”

Section: Discussionmentioning

confidence: 99%

Construction of a Lung Adenocarcinoma Prognostic Model Utilizing Serine and Glycine Metabolism-Related Genes

Qi,

Liu,

Zhang

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

The objective of this study was to construct a prognostic model by utilizing serine/glycine metabolism-related genes (SGMGs), thus establishing a risk score for lung adenocarcinoma (LUAD). Based on the TCGA-LUAD and SGMG data set, two subtypes with different SGMG expression levels were identified by clustering analysis. Thirteen differential expression genes were used to construct RiskScore by Cox regression. GSE72094 data set was used for validation. The survival characteristics, immune features, and potential benefits of chemotherapy drugs were analyzed for two risk groups. RiskScore was constructed based on the genes ABCC12, RIC3, CYP4B1, SFTPB, CACNA2D2, IGF2BP1, NTSR1, DKK1, CREG2, PITX3, RGS20, FETUB, and IGFBP1. Patients in the low-risk (LR) group exhibited a superior overall survival. In addition, aDCs, iDSs, mast cells, neutrophils, HLA, and type II IFN were more abundant in the LR group with higher IPS scores and lower TIDE scores. In contrast, NK cells, APC coinhibition, and MHC-I were more common in the high-risk (HR) group, which may be more sensitive to chemotherapy drugs such as cisplatin, oxaliplatin, and nilotinib. RiskScore was a promising biomarker that can be used to distinguish LUAD prognosis, immune features, and sensitivity to chemotherapy drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction of a Lung Adenocarcinoma Prognostic Model Utilizing Serine and Glycine Metabolism-Related Genes

Qi,

Liu,

Zhang

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

“…[24,25] For example, EIF4G1 mRNA levels were significantly elevated in breast cancer tissues compared to normal breast samples; BRCA patients with increased EIF4G1 expression had shorter overall survival in all cohorts; and patients with high expression of EIF4G1 responded better to immunotherapy; thus, EIF4G1 may be a valid predictor of the efficacy of immunotherapy in BRCA patients. [26] The study by Bhattacharyya et al describes in detail the biomarker-guided adaptive phase III clinical trials, where first we need to identify significant genes among a large number of evaluated differential genes by high-throughput screening methods; second, estimate the gene-treatment interaction effect; and lastly, utilize an unknown-gene adaptive signature design to assess the level of significance in selecting differentially expressed genes by Bonferroni adjustment and false discovery rate. [27] BZW1, a member of the bZIP transcription factor superfamily, is involved in the progression of multiple tumors.…”

Section: Discussionmentioning

confidence: 99%

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma

Luo,

Qiao,

et al. 2024

Medicine

View full text Add to dashboard Cite

Pancreatic adenocarcinoma is the most common malignant tumor of the digestive system and is called the “king of cancer” because it has been labeled with high malignancy, rapid progression, poor survival, and poor prognosis. Previously, it was reported that the basic leucine zipper and W2 domains 1 (BZW1) is involved in the progression of many tumors. However, its research in digestive system tumors such as pancreatic cancer is rarely studied. To explore potential biomarkers related to survival and prognosis of pancreatic cancer and provide a new targeted therapy for it. We first analyzed the mRNA and protein expression of BZW1 in pancreatic cancer. We then explored the correlation of BZW1 with survival prognosis and immune infiltration in pancreatic cancer patients. Finally, we explored BZW1-related gene enrichment analysis, including protein-protein interaction networks, gene ontology functional enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The mRNA and protein expression of the BZW1 gene in pancreatic cancer tissues were higher than those in adjacent normal tissues, and pancreatic cancer patients with high BZW1 expression had a poor prognosis. In addition, the expression of BZW1 was positively or negatively correlated with different immune cells of pancreatic cancer, such as CD4 + T lymphocytes, CD8 + T lymphocytes, B cells, macrophages, neutrophils, etc. Correlation enrichment analysis showed that we obtained 50 available experimentally determined BZW1-binding proteins and 100 targeted genes related to BZW1, and the intersection genes were eukaryotic translation termination factor 1 and Guanine nucleotide binding protein, alpha inhibiting activity polypeptide 3. Moreover, there was a positive correlation between BZW1 and eukaryotic translation termination factor 1 and Guanine nucleotide binding protein, alpha inhibiting activity polypeptide 3 genes in pancreatic cancer. Gene ontology enrichment analysis showed BZW1 was mainly related to biological processes such as “mRNA processing,” “RNA splicing,” “regulation of translational initiation,” and “activation of innate immune response.” The results of Kyoto Encyclopedia of Genes and Genomes pathway analysis further indicated that BZW1 may be involved in pancreatic carcinogenesis through the “spliceosome” and “ribosome.” The BZW1 gene may be a potential immunotherapy target and a promising prognostic marker for pancreatic cancer.

show abstract

“…Wang et al proposed that NCAPG2 could potentially function as a regulatory element and a biomarker for various malignancies [32]. Li et al demonstrated that EIF4G1 may have the ability to modify the tumor microenvironment and inhibit the metastasis of Breast cancer (BRCA), thus potentially serving as a prognostic biomarker and therapeutic target for BRCA [33]. Similarly, Zhao et al revealed that CYFIP2 could be considered a potential therapeutic target for both Rheumatoid arthritis (RA) and various types of tumors, offering a new perspective on the treatment of immune-related RA diseases and cancer [34].…”

Section: Discussionmentioning

confidence: 99%

SLC8A1, a novel prognostic biomarker and immunotherapy target in RSA and UCEC based on scRNA-seq and pan-cancer analysis

Chu,

Qin,

2023

Preprint

View full text Add to dashboard Cite

Purpose As the field of gynecological immunology increasingly focuses on reproduction, the importance of recurrent spontaneous abortion (RSA) is growing. The complex mechanisms underlying the interaction between RSA and cancer are still not well understood. This study seeks to identify a new prognostic biomarker for RSA and cancer. Methods Weighted Gene Co-Expression Network Analysis (WGCNA), single-cell RNA sequencing (scRNA-seq), and machine learning algorithms were utilized for the analysis of RSA decidua samples (GSE164449, GSE214607, GSE65099) to identify the hub gene. The expression and distribution of the hub gene were subsequently investigated using the pan-cancer database TCGA. Furthermore, a prognostic prediction was made to assess the hub gene's impact on cancer response, mutation burden, immunity microenvironment, immune checkpoint, and chemotherapy. Results SLC8A1 has been identified as a hub gene within the RAS. In pan-cancer analysis, SLC8A1 exhibited strong expression levels in UCEC. The efficacy of SLC8A1 as a predictive marker was substantiated by calibration curves and concordance index. The mutation rate of SLC8A1 was found to be 6% based on the waterfall plot. Immune analysis revealed notable differences in the fractions of T cells and macrophages between the high and low expression groups. The analysis of immune checkpoint has demonstrated notable associations with CD40positive immune checkpoints. Notably, patients classified in the low-risk group exhibited enhanced responsiveness to Osimertinib, Dasatinib, Sepantronium bromid, lbrutinib, and other treatments. Conclusion These findings suggest that SLC8A1 may serve as a promising prognostic biomarker and potential target for immunotherapy in the context of RSA and UCEC.

show abstract

EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer

Cited by 6 publications

References 53 publications

Construction of a Lung Adenocarcinoma Prognostic Model Utilizing Serine and Glycine Metabolism-Related Genes

Construction of a Lung Adenocarcinoma Prognostic Model Utilizing Serine and Glycine Metabolism-Related Genes

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma

SLC8A1, a novel prognostic biomarker and immunotherapy target in RSA and UCEC based on scRNA-seq and pan-cancer analysis

Contact Info

Product

Resources

About